Affibody AB of Sweden and Inmagene Biopharmaceuticals Ltd. of China have entered a strategic partnership to develop and commercialize the Swedish biotech’s lead asset, a bispecific molecule targeting Interleukin-17A for multiple auto-immune diseases that could be on the market within six years.
Their alliance, announced on 15 May, focuses on Affibody’s ABY-035, an innovative fusion protein that is in Phase II development...








